Brokers Offer Predictions for EPRX Q2 Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Analysts at HC Wainwright issued their Q2 2026 EPS estimates for shares of Eupraxia Pharmaceuticals in a research note issued to investors on Tuesday, March 17th. HC Wainwright analyst B. Folkes expects that the company will post earnings of ($0.20) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q4 2026 earnings at ($0.21) EPS and FY2030 earnings at $0.17 EPS.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.21).

A number of other analysts have also issued reports on EPRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen lowered Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Cantor Fitzgerald increased their price objective on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, January 15th. Finally, Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Eupraxia Pharmaceuticals has a consensus rating of “Buy” and an average price target of $15.00.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ EPRX opened at $7.51 on Wednesday. The stock has a 50-day simple moving average of $8.30 and a 200 day simple moving average of $6.87. Eupraxia Pharmaceuticals has a twelve month low of $2.68 and a twelve month high of $9.32. The stock has a market capitalization of $270.06 million, a PE ratio of -7.29 and a beta of 1.27.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several large investors have recently added to or reduced their stakes in EPRX. Quadrature Capital Ltd bought a new stake in shares of Eupraxia Pharmaceuticals in the 2nd quarter worth approximately $61,000. TCI Wealth Advisors Inc. bought a new stake in shares of Eupraxia Pharmaceuticals during the third quarter valued at approximately $65,000. Integrated Wealth Concepts LLC acquired a new position in shares of Eupraxia Pharmaceuticals in the third quarter valued at $71,000. Bank of America Corp DE raised its stake in shares of Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares in the last quarter. Finally, Guardian Wealth Advisors LLC NC bought a new position in Eupraxia Pharmaceuticals in the fourth quarter worth $76,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.